MyMD Pharmaceuticals, Inc.

( )
AKER PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -2.81%177.010.7%$1390.13m
MRKMerck & Co., Inc. -2.60%91.960.7%$1216.80m
PFEPfizer Inc. -2.29%50.690.9%$1177.94m
BMYBristol-Myers Squibb Co. -1.58%78.721.0%$1104.13m
LLYEli Lilly & Co. -2.91%317.751.1%$1091.72m
ABBVAbbVie, Inc. -0.40%152.531.9%$989.13m
AZNAstraZeneca Plc -0.87%65.931.0%$446.77m
SGENSeagen Inc. 0.42%178.475.7%$327.62m
TPTXTurning Point Therapeutics, Inc. -0.28%75.060.0%$295.90m
GSKGSK Plc -0.78%43.360.2%$285.09m
HZNPHorizon Therapeutics Plc -4.45%81.695.4%$176.63m
NVSNovartis AG -1.27%84.200.2%$166.38m
MRTXMirati Therapeutics, Inc. -1.67%68.501.6%$162.75m
NVONovo Nordisk A/S -4.04%108.330.1%$145.58m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.47%144.690.0%$142.13m

Company Profile

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.